OCUP Ocuphire Pharma Inc

Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced that George Magrath, M.D., Chief Executive Officer, will participate in a fireside chat during the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference, which will be available on demand on Wednesday, August 13, 2025 at 7:00 a.m. ET.

A link to the live and archived webcast may be accessed on Opus Genetics’ website under the Investors section: .

About Opus Genetics

Opus Genetics is a clinical-stage biopharmaceutical company developing gene and small molecule therapies for vision-threatening eye diseases. The Company’s pipeline features AAV-based gene therapies targeting inherited retinal diseases including Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa. Its lead candidate, OPGx-LCA5, is in a Phase 1/2 trial for LCA5-related mutations and has shown encouraging early results. Additional programs include OPGx-BEST1, a gene therapy targeting BEST1-related retinal degeneration and a Phase 3-ready small molecule therapy for diabetic retinopathy, developed under a Special Protocol Assessment with the FDA. Opus Genetics is also advancing Phentolamine Ophthalmic Solution 0.75%, a partnered therapy currently approved in one indication and is being studied in two Phase 3 programs for presbyopia and dim light vision disturbances. The Company is based in Research Triangle Park, NC. For more information, visit .

Contacts:

Investors

Jenny Kobin

Remy Bernarda

IR Advisory Solutions

Media

Kimberly Ha

KKH Advisors

917-291-5744



EN
05/08/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ocuphire Pharma Inc

 PRESS RELEASE

Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthal...

Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced that George Magrath, M.D., Chief Executive Officer, will participate in a fireside chat during the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference, which will be available on demand on Wednesday, August 13...

 PRESS RELEASE

Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 G...

Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness Collaboration aims to accelerate development of OPGx-RDH12, a gene therapy for RDH12-associated Leber congenital amaurosis (RDH12-LCA) RESEARCH TRIANGLE PARK, N.C., July 23, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced a strategic partnership with the Global RDH12 Alliance (the Al...

 PRESS RELEASE

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 56...

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) RESEARCH TRIANGLE PARK, N.C., July 03, 2025 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders (the “Company”), today announced that, on June 30, 2025, it granted equity awards to two new non-executive employees as a material inducement to employment. The equity awards were granted under the Company’s 2021 Inducement Plan, as amended, and ...

 PRESS RELEASE

Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint ...

Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia Study met its primary and key secondary endpoints, demonstrating rapid and sustained improvement in near visual acuitySafety profile consistent with previous clinical trials and no treatment-related serious adverse events reported in the studyNo evidence of tachyphylaxis was observed in this study over the 6-week periodManagement to Host Webcast and Conference Call Today at 8:00 A.M. ET RESEARCH TRIANGLE PARK, N.C., June 26, 2025 (GLOBE NEWSWIRE...

 PRESS RELEASE

Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support...

Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program RESEARCH TRIANGLE PARK, N.C., June 23, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, recently disclosed that the Retinal Degeneration Fund (RD Fund), the venture philanthropy arm of the Foundation Fighting Blindness, has entered into a funding agreement with Opus providing for up to $2 ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch